北京若生智能科技有限公司
Drug Database
MO

montelukast (Montefree)

✓ Approved

SK Chemicals · CYSLTR1 · 小分子

什么是 montelukast？

montelukast 是一种小分子，由SK Chemicals研发。该药已获批，用于治疗相关适应症，给药途径：Oral (PO)。

药物档案

商品名Montefree
公司SK Chemicals
药物类别小分子
分子靶点CYSLTR1
给药途径Oral (PO)
状态Approved
来源： ClinicalTrials.gov, SK Chemicals

作用机制

分子靶点

montelukast 作用于 1 个分子靶点：

CYSLTR1cysteinyl leukotriene receptor 1 (CYSLTR, CYSLT1)
需要更深入的分析？Noah AI 可解释复杂机制并与同类药物比较。

治疗适应症

montelukast 针对 3 个适应症，涉及 2 个治疗领域。

治疗领域疾病/病症分期
Respiratory, thoracic and mediastinal disordersAsthma✓ Approved
Respiratory, thoracic and mediastinal disordersRhinitis allergic✓ Approved
Immune system disordersSeasonal allergy✓ Approved

相关研究文献

PubMedGels (Basel, Switzerland)2026-10-26

Preparation of a Lotus-Leaf-Inspired PVA-Grape Seed Extract Biomimetic Gel Film and Its Application in Active Packaging for the Postharvest Preservation of Agaricus bisporus.

Wang Liyan L, Sun Lingyu L, Zhang Yixuan Y, Cong Mengdi M et al.

This study reports the fabrication of a biomimetic PVA-GSE film featuring a lotus-leaf-like hierarchical micro/nanostructure, and its application as a gel-based active packaging material for the post-harvest preservation of Agaricus bisporus (A. bisporus). A lotus-leaf negative template was prepared using soft etching and a polydimethylsiloxane (PDMS) secondary transfer method; the PVA/GSE solution was then cast onto this template and subjected to repeated freeze-thaw cycles for physical cross-linking to induce PVA hydrogelation. The resulting biomimetic gel film reproduces the hierarchical lotus-leaf surface morphology and forms a continuous polymer gel network composed of interconnected gel pores, which serve as reservoirs for grape seed extract (GSE). This gel network structure enhances the properties of PVA. Although BPG-40 exhibited the strongest preservation performance during storage owing to its highest GSE loading, BPG-30 was selected as the optimal formulation, because it achieved the best overall balance of mechanical strength, water-vapour barrier and optical quality while retaining 91-93% of the BPG-40 antioxidant and antibacterial activity; beyond 30% loading, the marginal gains in bioactivity were outweighed by a 12.6% decrease in tensile strength, severe colour darkening (L* = 6.07) and surface cracks observed by SEM. An experiment was conducted to evaluate the effects of the biomimetic composite film on A. bisporus over a 12 days storage period at 4 °C. Storage results demonstrate that this film effectively reduces the weight loss rate of A. bisporus, lowers their respiration rate, enhances the polyphenol retention rate, and significantly extends the storage life of A. bisporus. This study simulates the surface structural regulation mechanism of lotus leaves and represents an innovative approach that synergistically integrates active ingredients with material structure for use in fresh-keeping packaging materials.

PMID 42929915
阅读全文 →
PubMedBiosensors2026-10-26

Detection of Buried Landmines in an Active Minefield Through Bioreporter-Based Optoelectronic Sensing of Their Chemical Signatures.

Uziel Yonatan Y, Adgo Mulkan M, Orlov Natan N, Shohat Roni R et al.

The research presented herein provides a first demonstration and a proof of concept of using sensing bacteria (bioreporters) to detect the chemical signatures generated by buried TNT-based landmines in an active minefield. The methodology, based on bioreporters generating a measurable signal in the presence of these chemicals, is fundamentally different from conventional approaches by detecting the explosive component of the device rather than its shape or metallic content. Furthermore, by virtue of the versatility of bioreporters to detect a broad range of target chemicals, the methodology can potentially be adapted to detect other types of explosives through the development of dedicated bioreporters. The measurements also highlight the potential of the biosensing modules to act as nodes in a sensor network for implementing the methodology across large areas. The methodology for detecting TNT via bacterial biosensing can be implemented in alternative configurations, enabling additional applications such as the identification of concealed TNT in cargo containers, buildings, and other environments.

PMID 42930086
阅读全文 →
PubMedThe New England journal of medicine2026-10-26

Divarasib as Compared with Sotorasib or Adagrasib in KRAS G12C-Mutated NSCLC.

Skoulidis Ferdinandos F, Ahn Myung-Ju MJ, Gadgeel Shirish S, Popat Sanjay S et al.

Divarasib, a next-generation, oral KRAS G12C inhibitor, is more potent and selective in vitro than the first-generation KRAS G12C inhibitors sotorasib and adagrasib. In this phase 3, international, open-label trial, patients with previously treated KRAS G12C-mutated advanced or metastatic non-small-cell lung cancer (NSCLC) were randomly assigned to receive divarasib orally at a dose of 400 mg once daily or control treatment (sotorasib orally at a dose of 960 mg once daily or adagrasib orally at a dose of 600 mg twice daily) until the occurrence of disease progression, unacceptable adverse events, loss of clinical benefit, withdrawal of consent, death, or trial termination. The primary end point was progression-free survival as assessed by blinded independent central review. Secondary end points included overall survival, confirmed overall response, duration of response, patient-reported outcomes, and safety. A total of 338 patients received divarasib (167 patients) or control treatment (171 patients; 156 received sotorasib and 15 received adagrasib). The median follow-up was 14.3 months. The median progression-free survival was 9.8 months with divarasib and 5.7 months with control treatment (hazard ratio for disease progression or death, 0.58; 95% confidence interval [CI], 0.44 to 0.76; P<0.001). The median overall survival was 17.7 months with divarasib and 12.0 months with control treatment (hazard ratio for death, 0.56; 95% CI, 0.41 to 0.78; P<0.001). Of the 328 patients who could be evaluated for response, a confirmed response occurred in 58.4% in the divarasib group and in 32.3% in the control group. The median duration of response was 11.9 months with divarasib and 6.9 months with control treatment. Fewer grade 3 or 4 treatment-related adverse events were noted with divarasib (24.6%) than with control treatment (34.5%). Among patients with previously treated KRAS G12C-mutated advanced or metastatic NSCLC, divarasib led to significantly longer progression-free and overall survival than control treatment. (Supported by F. Hoffmann-La Roche; Krascendo 1 ClinicalTrials.gov number, NCT06497556.).

PMID 42929675
阅读全文 →
PubMedInorganic chemistry2026-10-26

Flexible Transparent Scintillation Films Based on Chiral Molecular Scintillators Showing Strong Circularly Polarized Luminescence and High-Resolution X-ray Imaging.

Tan Li-Hong LH, Yin Si-En SE, Shi Jia-Ran JR, Hu Jun-Jie JJ et al.

Flexible scintillation films based on chiral molecular scintillators have considerable potential for application in advanced technologies, such as three-dimensional displays, optical information storage, and high-resolution diagnostic imaging. Herein, a pair of chiral Cd-Tb complex enantiomers [(R, R)/(S, S)-(L)2TbCd2(H2O)4] (ClO4)3 (R/S -Cd-Tb) was synthesized, and they exhibit a high PLQY of 38.40% and strong circularly polarized luminescence (CPL) with asymmetry factors of 4.69 × 10-2. R/S -Cd-Tb has strong X-ray scintillation performance with a light yield of 2136 and 2111 ph·MeV-1 based on LuAG:Ce and the X-ray detection limit of 50.6 and 52.1 nGy·s-1, respectively. Chiral flexible transparent scintillation films of R/S -Cd-Tb@PMMA were prepared using R/S -Cd-Tb, and the asymmetry factor of the R/S -Cd-Tb@PMMA film is 2.4 × 10-2. The R/S -Cd-Tb@PMMA film exhibits strong circularly polarized radioluminescence (CPRL) and circularly polarized light-emitting diode emission (CP-LEDs). Moreover, it can deliver prominent CPRL signals and achieve high-resolution X-ray imaging with a spatial resolution of 23.96 lp/mm. The results indicate that chiral lanthanide complexes represent a promising class of chiral molecular scintillator materials.

PMID 42929642
阅读全文 →
PubMedToxicological sciences : an official journal of the Society of Toxicology2026-10-26

Modernising cosmetic chemical safety assessment: an updated workflow.

Dent Matthew P MP, Mahony Catherine C, Najjar Abdulkarim A, Ouedraogo Gladys G et al.

We present an updated workflow for safety assessment of human systemic toxicity of cosmetic chemicals that is exposure-led and hypothesis driven and adapted from that proposed by the SEURAT-1 European program, taking account of day-to-day realities faced by cosmetic ingredient risk assessors. The workflow utilizes pre-existing legacy in vivo toxicity data for target chemicals and chemically and biologically suitable analogues. These are considered alongside human exposure data and are complemented by data provided by in silico and in vitro new-approach methodologies, when needed to build confidence in the safety decision or when legacy in vivo toxicity data are unavailable. The workflow specifies three consecutive Tiers. Tier 0 involves problem formulation and collection of existing data; if this provides sufficient certainty in a safety decision, further work is not needed. Tier 1 focuses on further hypothesis generation, plus data generation to explore (and potentially generate) hypotheses and quantify points of departure. Tier 2 encompasses further refinement activities that may be required if activities undertaken in Tiers 0 and 1 are insufficient. The workflow differs from existing frameworks by providing clear exit points, explicit integration of new approach methodologies-supported read-across and a practical structure for systemic toxicity decision making without new animal data generation. We have highlighted aspects that will benefit from further development and improvement - most notably, Tier 2 refinement. Case studies are presented that illustrate how the updated workflow is ready for practical use in cosmetic chemical safety assessments. We recommend its adoption in future cosmetic ingredient regulatory submissions.

PMID 42928603
阅读全文 →
PubMedAdvanced materials (Deerfield Beach, Fla.)2026-10-26

Natural Versus Artificial Photosynthesis: Pushing Beyond Nature's Limits to Deliver Low-Cost Solar Fuels.

Guo Tianxin T, Wang Zicheng Z, Waterhouse Geoffrey I N GIN, Zhao Yunxuan Y et al.

Natural photosynthesis (NP) sustains life by coordinating light harvesting, charge separation, multielectron catalysis, carbon fixation, regulation, and repair. Artificial photosynthesis instead aims to convert solar energy selectively into fuels and chemicals through designed light absorbers, interfaces, and catalytic sites. This review compares the two systems across light harvesting, charge separation and transfer, catalytic conversion, photoprotection, and system integration, emphasizing that meaningful comparisons require similar functions, comparable metrics, and clearly defined system boundaries. Field-scale NP typically operates at sub-percent solar-to-biomass efficiencies, whereas selected artificial photosynthetic devices have achieved double-digit solar-to-fuel efficiencies under defined conditions. These values should not be directly ranked because the products and system functions differ. We identify the respective strengths of artificial systems in spectral, interfacial, catalytic, and product control, and of natural systems in regulation, repair, regeneration, and multiscale coordination, providing design principles for efficient, durable, and scalable solar-to-chemical conversion.

PMID 42929055
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多montelukast